| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 498 | 2021 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 471 | 2016 |
| TORC1 is essential for NF1-associated malignancies CM Johannessen, BW Johnson, SMG Williams, AW Chan, EE Reczek, ... Current Biology 18 (1), 56-62, 2008 | 228 | 2008 |
| Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch S Giuriato, S Ryeom, AC Fan, P Bachireddy, RC Lynch, MJ Rioth, ... Proceedings of the National Academy of Sciences 103 (44), 16266-16271, 2006 | 190 | 2006 |
| Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth S Ryeom, KH Baek, MJ Rioth, RC Lynch, A Zaslavsky, A Birsner, SS Yoon, ... Cancer cell 13 (5), 420-431, 2008 | 137 | 2008 |
| Immune checkpoint inhibitors in NSCLC DB Johnson, MJ Rioth, L Horn Current treatment options in oncology 15, 658-669, 2014 | 102 | 2014 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016; 4 (11): 959–967. doi: 10.1158/2326-6066 DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... CIR-16-0143.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 81 | |
| SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care JL Warner, MJ Rioth, KD Mandl, JC Mandel, DA Kreda, IS Kohane, ... Journal of the American Medical Informatics Association 23 (4), 701-710, 2016 | 66 | 2016 |
| Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium P Beaudry, M Nilsson, M Rioth, D Prox, D Poon, L Xu, P Zweidler-Mckay, ... Molecular cancer therapeutics 7 (2), 418-424, 2008 | 57 | 2008 |
| Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial RD Carvajal, MO Butler, AN Shoushtari, JC Hassel, A Ikeguchi, ... Nature medicine 28 (11), 2364-2373, 2022 | 56 | 2022 |
| ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms KL Couts, J Bemis, JA Turner, SM Bagby, D Murphy, J Christiansen, ... Molecular cancer therapeutics 17 (1), 222-231, 2018 | 45 | 2018 |
| Integrated biomarkers for the management of indeterminate pulmonary nodules MN Kammer, DA Lakhani, AB Balar, SL Antic, AK Kussrow, RL Webster, ... American journal of respiratory and critical care medicine 204 (11), 1306-1316, 2021 | 40 | 2021 |
| Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience CL Aquilante, DP Kao, KE Trinkley, CT Lin, KR Crooks, EC Hearst, ... Pharmacogenomics 21 (6), 375-386, 2020 | 39 | 2020 |
| 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe)(IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM) JJ Sacco, R Carvajal, MO Butler, AN Shoushtari, JC Hassel, A Ikeguchi, ... Annals of Oncology 31, S1442-S1443, 2020 | 37 | 2020 |
| Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology MJ Rioth, J Warner, BN Savani, M Jagasia Bone Marrow Transplantation 51 (1), 34-40, 2016 | 25 | 2016 |
| A phase II study of glembatumumab vedotin for metastatic uveal melanoma M Hasanov, MJ Rioth, K Kendra, L Hernandez-Aya, RW Joseph, ... Cancers 12 (8), 2270, 2020 | 21 | 2020 |
| Pre-treatment mutational and transcriptomic landscape of responding metastatic melanoma patients to anti-PD1 immunotherapy CM Amato, JD Hintzsche, K Wells, A Applegate, NT Gorden, VM Vorwald, ... Cancers 12 (7), 1943, 2020 | 19 | 2020 |
| A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making C Friedman, M Lyon, RJ Torphy, D Thieu, P Hosokawa, R Gonzalez, ... Journal of Surgical Oncology 120 (7), 1276-1283, 2019 | 19 | 2019 |
| Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. DB Johnson, GM Frampton, MJ Rioth, E Yusko, R Ennis, D Fabrizio, ... Journal of Clinical Oncology 34 (15_suppl), 105-105, 2016 | 18 | 2016 |
| Change management for the successful adoption of clinical information systems CU Lehmann, KM Unertl, MJ Rioth, NM Lorenzi Clinical Informatics Study Guide: Text and Review, 435-456, 2016 | 11 | 2016 |
Douglas B JohnsonAssociate Professor of Medicine, Vanderbilt University Medical CenterBestätigte E-Mail-Adresse bei vumc.org
